Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.

Masonou T, Hokey DA, Lahey T, Halliday A, Berrocal-Almanza LC, Wieland-Alter WF, Arbeit RD, Lalvani A, von Reyn CF.

PLoS One. 2019 May 23;14(5):e0217091. doi: 10.1371/journal.pone.0217091. eCollection 2019.

2.

Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.

Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M; C-040-404 Study Team.

N Engl J Med. 2018 Jul 12;379(2):138-149. doi: 10.1056/NEJMoa1714021.

3.

The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010-2014.

Brennan MJ, Tanner R, Morris S, Scriba TJ, Achkar JM, Zelmer A, Hokey DA, Izzo A, Sharpe S, Williams A, Penn-Nicholson A, Erasmus M, Stylianou E, Hoft DF, McShane H, Fletcher HA.

Clin Vaccine Immunol. 2017 Sep 5;24(9). pii: e00142-17. doi: 10.1128/CVI.00142-17. Print 2017 Sep. Review.

4.

Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.

von Reyn CF, Lahey T, Arbeit RD, Landry B, Kailani L, Adams LV, Haynes BC, Mackenzie T, Wieland-Alter W, Connor RI, Tvaroha S, Hokey DA, Ginsberg AM, Waddell R.

PLoS One. 2017 May 12;12(5):e0175215. doi: 10.1371/journal.pone.0175215. eCollection 2017.

5.

Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.

Norrby M, Vesikari T, Lindqvist L, Maeurer M, Ahmed R, Mahdavifar S, Bennett S, McClain JB, Shepherd BM, Li D, Hokey DA, Kromann I, Hoff ST, Andersen P, de Visser AW, Joosten SA, Ottenhoff THM, Andersson J, Brighenti S.

Vaccine. 2017 Mar 14;35(12):1652-1661. doi: 10.1016/j.vaccine.2017.01.055. Epub 2017 Feb 17.

6.

Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.

van Zyl-Smit RN, Esmail A, Bateman ME, Dawson R, Goldin J, van Rikxoort E, Douoguih M, Pau MG, Sadoff JC, McClain JB, Snowden MA, Benko J, Hokey DA, Rutkowski KT, Graves A, Shepherd B, Ishmukhamedov S, Kagina BMN, Abel B, Hanekom WA, Scriba TJ, Bateman ED.

Am J Respir Crit Care Med. 2017 May 1;195(9):1171-1180. doi: 10.1164/rccm.201603-0654OC.

PMID:
28060545
7.

A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis.

Zelmer A, Tanner R, Stylianou E, Damelang T, Morris S, Izzo A, Williams A, Sharpe S, Pepponi I, Walker B, Hokey DA, McShane H, Brennan M, Fletcher H.

BMC Infect Dis. 2016 Aug 12;16:412. doi: 10.1186/s12879-016-1751-4.

8.

Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial.

Hoft DF, Blazevic A, Selimovic A, Turan A, Tennant J, Abate G, Fulkerson J, Zak DE, Walker R, McClain B, Sadoff J, Scott J, Shepherd B, Ishmukhamedov J, Hokey DA, Dheenadhayalan V, Shankar S, Amon L, Navarro G, Podyminogin R, Aderem A, Barker L, Brennan M, Wallis RS, Gershon AA, Gershon MD, Steinberg S.

EBioMedicine. 2016 May;7:278-86. doi: 10.1016/j.ebiom.2016.04.010. Epub 2016 Apr 19.

9.

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.

Sheehan S, Harris SA, Satti I, Hokey DA, Dheenadhayalan V, Stockdale L, Manjaly Thomas ZR, Minhinnick A, Wilkie M, Vermaak S, Meyer J, O'Shea MK, Pau MG, Versteege I, Douoguih M, Hendriks J, Sadoff J, Landry B, Moss P, McShane H.

PLoS One. 2015 Nov 3;10(11):e0141687. doi: 10.1371/journal.pone.0141687. eCollection 2015.

10.

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

Graves AJ, Hokey DA.

Hum Vaccin Immunother. 2015;11(8):1910-6. doi: 10.1080/21645515.2015.1040955.

11.

A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

Tameris M, Hokey DA, Nduba V, Sacarlal J, Laher F, Kiringa G, Gondo K, Lazarus EM, Gray GE, Nachman S, Mahomed H, Downing K, Abel B, Scriba TJ, McClain JB, Pau MG, Hendriks J, Dheenadhayalan V, Ishmukhamedov S, Luabeya AK, Geldenhuys H, Shepherd B, Blatner G, Cardenas V, Walker R, Hanekom WA, Sadoff J, Douoguih M, Barker L, Hatherill M.

Vaccine. 2015 Jun 9;33(25):2944-54. doi: 10.1016/j.vaccine.2015.03.070. Epub 2015 Apr 28.

PMID:
25936724
12.

TB Vaccines: The (Human) Challenge Ahead.

Hokey DA.

Mycobact Dis. 2014 Aug;4(4):e128. No abstract available.

13.

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.

van Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA, O'Dee DM, Graves A, Thierry-Carstensen B, Andreasen LV, Ruhwald M, de Visser AW, Agger EM, Ottenhoff TH, Kromann I, Andersen P.

Vaccine. 2014 Dec 12;32(52):7098-107. doi: 10.1016/j.vaccine.2014.10.036. Epub 2014 Oct 30.

14.

A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs.

Hokey DA, Wachholder R, Darrah PA, Bolton DL, Barouch DH, Hill K, Dheenadhayalan V, Schwander S, Godin CS, Douoguih M, Pau MG, Seder RA, Roederer M, Sadoff JC, Sizemore D.

Hum Vaccin Immunother. 2014;10(8):2199-210. doi: 10.4161/hv.29108.

15.

The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.

Kagina BM, Tameris MD, Geldenhuys H, Hatherill M, Abel B, Hussey GD, Scriba TJ, Mahomed H, Sadoff JC, Hanekom WA; 018-402 Clinical Lab study team, Mansoor N, Hughes J, de Kock M, Whatney W, Africa H, Krohn C, Veldsman A, Kany AL, Douoguih M, Pau MG, Hendriks J, McClainc B, Benko J, Snowden MA, Hokey DA.

Vaccine. 2014 Oct 14;32(45):5908-17. doi: 10.1016/j.vaccine.2014.09.001. Epub 2014 Sep 10.

PMID:
25218194
16.

Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.

Darrah PA, Bolton DL, Lackner AA, Kaushal D, Aye PP, Mehra S, Blanchard JL, Didier PJ, Roy CJ, Rao SS, Hokey DA, Scanga CA, Sizemore DR, Sadoff JC, Roederer M, Seder RA.

J Immunol. 2014 Aug 15;193(4):1799-811. doi: 10.4049/jimmunol.1400676. Epub 2014 Jul 14.

17.

The frequencies of IFNγ+IL2+TNFα+ PPD-specific CD4+CD45RO+ T-cells correlate with the magnitude of the QuantiFERON® gold in-tube response in a prospective study of healthy indian adolescents.

Jenum S, Grewal HM, Hokey DA, Kenneth J, Vaz M, Doherty TM, Jahnsen FL; TB Trials Study Group.

PLoS One. 2014 Jul 3;9(7):e101224. doi: 10.1371/journal.pone.0101224. eCollection 2014.

18.

OMIP-022: Comprehensive assessment of antigen-specific human T-cell functionality and memory.

Graves AJ, Padilla MG, Hokey DA.

Cytometry A. 2014 Jul;85(7):576-9. doi: 10.1002/cyto.a.22478. Epub 2014 May 27. No abstract available.

19.

The current state of tuberculosis vaccines.

Hokey DA, Ginsberg A.

Hum Vaccin Immunother. 2013 Oct;9(10):2142-6. doi: 10.4161/hv.25427. Epub 2013 Jun 21. Review.

20.

Immune modulation through 4-1BB enhances SIV vaccine protection in non-human primates against SIVmac251 challenge.

Hirao LA, Hokey DA, Morrow MP, Jure-Kunkel MN, Weiner DB.

PLoS One. 2011;6(9):e24250. doi: 10.1371/journal.pone.0024250. Epub 2011 Sep 15.

21.

Aerosol vaccines for tuberculosis: a fine line between protection and pathology.

Hokey DA, Misra A.

Tuberculosis (Edinb). 2011 Jan;91(1):82-5. doi: 10.1016/j.tube.2010.09.007. Epub 2010 Nov 9. Review.

PMID:
21067975
22.

Ki-67 staining for determination of rhesus macaque T cell proliferative responses ex vivo.

Shedlock DJ, Talbott KT, Morrow MP, Ferraro B, Hokey DA, Muthumani K, Weiner DB.

Cytometry A. 2010 Mar;77(3):275-84. doi: 10.1002/cyto.a.20857.

23.

Novel SIVmac DNA vaccines encoding Env, Pol and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques.

Yan J, Hokey DA, Morrow MP, Corbitt N, Harris K, Harris D, Weiner DB.

Vaccine. 2009 May 26;27(25-26):3260-6. doi: 10.1016/j.vaccine.2009.01.065. Epub 2009 Feb 5.

PMID:
19200811
24.

CLTA-4 blockade in vivo promotes the generation of short-lived effector CD8 T cells and a more persistent central memory CD4 T cell response.

Hokey DA, Yan J, Hirao LA, Dai A, Boyer JD, Jure-Kunkel MN, Weiner DB.

J Med Primatol. 2008 Dec;37 Suppl 2:62-8. doi: 10.1111/j.1600-0684.2008.00324.x.

PMID:
19187432
25.

Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.

Yan J, Reichenbach DK, Corbitt N, Hokey DA, Ramanathan MP, McKinney KA, Weiner DB, Sewell D.

Vaccine. 2009 Jan 14;27(3):431-40. doi: 10.1016/j.vaccine.2008.10.078. Epub 2008 Nov 18.

26.

Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques.

Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, Betts MR, Draghia-Akli R, Weiner DB.

Vaccine. 2008 Jun 13;26(25):3112-20. doi: 10.1016/j.vaccine.2008.02.036. Epub 2008 Mar 11.

27.

Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques.

Hokey DA, Johnson FB, Smith J, Weber JL, Yan J, Hirao L, Boyer JD, Lewis MG, Makedonas G, Betts MR, Weiner DB.

Eur J Immunol. 2008 May;38(5):1435-45. doi: 10.1002/eji.200737857.

28.

Augmentation of SIV DNA vaccine-induced cellular immunity by targeting the 4-1BB costimulatory molecule.

Calarota SA, Hokey DA, Dai A, Jure-Kunkel MN, Balimane P, Weiner DB.

Vaccine. 2008 Jun 13;26(25):3121-34. doi: 10.1016/j.vaccine.2008.02.017. Epub 2008 Feb 22.

PMID:
18336959
29.

Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid.

Boyer JD, Robinson TM, Kutzler MA, Vansant G, Hokey DA, Kumar S, Parkinson R, Wu L, Sidhu MK, Pavlakis GN, Felber BK, Brown C, Silvera P, Lewis MG, Monforte J, Waldmann TA, Eldridge J, Weiner DB.

Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18648-53. Epub 2007 Nov 13.

30.

Phagocytosis induces lysosome remodeling and regulated presentation of particulate antigens by activated dendritic cells.

Nayak JV, Hokey DA, Larregina A, He Y, Salter RD, Watkins SC, Falo LD Jr.

J Immunol. 2006 Dec 15;177(12):8493-503.

31.

Immunostimulation of dendritic cells by cationic liposomes.

Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD Jr, Huang L.

Mol Membr Biol. 2006 Sep-Oct;23(5):385-95.

PMID:
17060156
32.

DNA vaccines for HIV: challenges and opportunities.

Hokey DA, Weiner DB.

Springer Semin Immunopathol. 2006 Nov;28(3):267-79. Epub 2006 Oct 10. Review.

PMID:
17031649
33.

Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.

Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD Jr.

Cancer Res. 2005 Nov 1;65(21):10059-67.

Supplemental Content

Loading ...
Support Center